Allogene Therapeutics Inc (ALLO) 옵션

ALLO...$2.08...🥳...Reversal Candle off the $1.80 range bottom...

georgie18

Member Level
Re: georgie18 post# 385710

Friday, December 13, 2024 2:38:52 PM

Post#
386948
of 387046
ALLO...$1.85...🥳Look like tax selling to me...Scooping up the dip...

georgie18

Member Level
Re: georgie18 post# 664158

Friday, November 15, 2024 11:35:10 AM

Post#
665142
of 667755
ALLO...$2.35...Bottoming out here...🥳They have 400 Million cash reserve...get them through mid 2026...

ALLO...$1.85...🥳Look like tax selling to me...Scooping up the dip...

georgie18

Member Level
Re: georgie18 post# 664158

Friday, November 15, 2024 11:35:10 AM

Post#
665142
of 667755
ALLO...$2.35...Bottoming out here...🥳They have 400 Million cash reserve...get them through mid 2026...

ALLO...$2.35...Bottoming out here...🥳They have 400 Million cash reserve...get them through mid 2026...

Have a Great Weekend Y'all...🥳

ALLO...$3.19...🥳...https://finance.yahoo.com/news/allogene-therapeutics-inc-allo-q3-110724066.html

ALLO...$3.31...Fins after todays close...🥳

georgie18

Member Level
Re: georgie18 post# 385280

Wednesday, November 06, 2024 10:27:01 AM

Post#
385286
of 385334
ALLO...$3.22s clearing here...🥳...Looking for the $5.78 Breakout... https://schrts.co/wITCFkcf

georgie18

Member Level
Re: georgie18 post# 663758

Wednesday, November 06, 2024 10:06:32 AM

Post#
663791
of 663807
ALLO...$3.17...HOD...🥳

georgie18

Member Level
Re: georgie18 post# 385240

Wednesday, November 06, 2024 7:12:20 AM

Post#
385251
of 385279
ALLO...$3.10...🥳

georgie18

Member Level
Re: georgie18 post# 663652

Tuesday, November 05, 2024 3:37:32 PM

Post#
663738
of 663757
ALLO...$3 ...starting up again...🥳

georgie18

Member Level
Re: georgie18 post# 385217

Tuesday, November 05, 2024 9:15:04 AM

Post#
385226
of 385239
ALLO...$2.98...News...ALLO-316, an “Off-the-Shelf” AlloCAR T™ Anti-CD70 CAR T Product, is Currently Under Investigation in the Phase 1 TRAVERSE Trial for Patients with Renal Cell Carcinoma (RCC) Previously Treated with Immune Checkpoint Inhibitors and VEGF-Targeting Therapies
Data Presented Advances Scientific Understanding and Applicability of the Dagger® Technology as the Next-Generation Allogeneic Platform to Maximize the Potential of a Single Infusion, AlloCAR T Product
Ongoing Phase 1 Data Supported the FDA's Recent RMAT Designation for ALLO-316 as a Promising Treatment to Address an Unmet Medical Need for Adults with Advanced or Metastatic CD70 Positive RCC Who Have Failed Standard RCC Therapies
SOUTH SAN FRANCISCO, Calif., Nov. 05, 2024 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) products for cancer and autoimmune disease, today announced that it will present new data from the ongoing Phase 1 TRAVERSE trial at the 2024 International Kidney Cancer Symposium (IKCS) and the Society for Immunotherapy of Cancer's (SITC) annual meeting. The trial evaluates ALLO-316, the Company’s first AlloCAR T product candidate for the potential treatment of solid tumors. These presentations will highlight data from 26 heavily pretreated patients with CD70 positive renal cell carcinoma (RCC) and will include details on the diagnostic and treatment algorithm used to mitigate treatment-associated hyperinflammatory response seen in some patients. The ongoing Phase 1 data supported the U.S. Food and Drug Administration’s (FDA) October 2024 decision to grant Regenerative Medicine Advanced Therapy (RMAT) designation for ALLO-316 based on clinical data from the TRAVERSE trial indicating its to address the unmet need for adult patients with advanced or metastatic CD70 positive RCC who have failed multiple standard RCC therapies, including an immune checkpoint inhibitor and a VEGF-targeting therapy.

ALLO...$3.22s clearing here...🥳...Looking for the $5.78 Breakout... https://schrts.co/wITCFkcf

georgie18

Member Level
Re: georgie18 post# 663758

Wednesday, November 06, 2024 10:06:32 AM

Post#
663791
of 663807
ALLO...$3.17...HOD...🥳

georgie18

Member Level
Re: georgie18 post# 385240

Wednesday, November 06, 2024 7:12:20 AM

Post#
385251
of 385279
ALLO...$3.10...🥳

georgie18

Member Level
Re: georgie18 post# 663652

Tuesday, November 05, 2024 3:37:32 PM

Post#
663738
of 663757
ALLO...$3 ...starting up again...🥳

georgie18

Member Level
Re: georgie18 post# 385217

Tuesday, November 05, 2024 9:15:04 AM

Post#
385226
of 385239
ALLO...$2.98...News...ALLO-316, an “Off-the-Shelf” AlloCAR T™ Anti-CD70 CAR T Product, is Currently Under Investigation in the Phase 1 TRAVERSE Trial for Patients with Renal Cell Carcinoma (RCC) Previously Treated with Immune Checkpoint Inhibitors and VEGF-Targeting Therapies
Data Presented Advances Scientific Understanding and Applicability of the Dagger® Technology as the Next-Generation Allogeneic Platform to Maximize the Potential of a Single Infusion, AlloCAR T Product
Ongoing Phase 1 Data Supported the FDA's Recent RMAT Designation for ALLO-316 as a Promising Treatment to Address an Unmet Medical Need for Adults with Advanced or Metastatic CD70 Positive RCC Who Have Failed Standard RCC Therapies
SOUTH SAN FRANCISCO, Calif., Nov. 05, 2024 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) products for cancer and autoimmune disease, today announced that it will present new data from the ongoing Phase 1 TRAVERSE trial at the 2024 International Kidney Cancer Symposium (IKCS) and the Society for Immunotherapy of Cancer's (SITC) annual meeting. The trial evaluates ALLO-316, the Company’s first AlloCAR T product candidate for the potential treatment of solid tumors. These presentations will highlight data from 26 heavily pretreated patients with CD70 positive renal cell carcinoma (RCC) and will include details on the diagnostic and treatment algorithm used to mitigate treatment-associated hyperinflammatory response seen in some patients. The ongoing Phase 1 data supported the U.S. Food and Drug Administration’s (FDA) October 2024 decision to grant Regenerative Medicine Advanced Therapy (RMAT) designation for ALLO-316 based on clinical data from the TRAVERSE trial indicating its to address the unmet need for adult patients with advanced or metastatic CD70 positive RCC who have failed multiple standard RCC therapies, including an immune checkpoint inhibitor and a VEGF-targeting therapy.

ALLO...$3.17...HOD...🥳

georgie18

Member Level
Re: georgie18 post# 385240

Wednesday, November 06, 2024 7:12:20 AM

Post#
385251
of 385279
ALLO...$3.10...🥳

georgie18

Member Level
Re: georgie18 post# 663652

Tuesday, November 05, 2024 3:37:32 PM

Post#
663738
of 663757
ALLO...$3 ...starting up again...🥳

georgie18

Member Level
Re: georgie18 post# 385217

Tuesday, November 05, 2024 9:15:04 AM

Post#
385226
of 385239
ALLO...$2.98...News...ALLO-316, an “Off-the-Shelf” AlloCAR T™ Anti-CD70 CAR T Product, is Currently Under Investigation in the Phase 1 TRAVERSE Trial for Patients with Renal Cell Carcinoma (RCC) Previously Treated with Immune Checkpoint Inhibitors and VEGF-Targeting Therapies
Data Presented Advances Scientific Understanding and Applicability of the Dagger® Technology as the Next-Generation Allogeneic Platform to Maximize the Potential of a Single Infusion, AlloCAR T Product
Ongoing Phase 1 Data Supported the FDA's Recent RMAT Designation for ALLO-316 as a Promising Treatment to Address an Unmet Medical Need for Adults with Advanced or Metastatic CD70 Positive RCC Who Have Failed Standard RCC Therapies
SOUTH SAN FRANCISCO, Calif., Nov. 05, 2024 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) products for cancer and autoimmune disease, today announced that it will present new data from the ongoing Phase 1 TRAVERSE trial at the 2024 International Kidney Cancer Symposium (IKCS) and the Society for Immunotherapy of Cancer's (SITC) annual meeting. The trial evaluates ALLO-316, the Company’s first AlloCAR T product candidate for the potential treatment of solid tumors. These presentations will highlight data from 26 heavily pretreated patients with CD70 positive renal cell carcinoma (RCC) and will include details on the diagnostic and treatment algorithm used to mitigate treatment-associated hyperinflammatory response seen in some patients. The ongoing Phase 1 data supported the U.S. Food and Drug Administration’s (FDA) October 2024 decision to grant Regenerative Medicine Advanced Therapy (RMAT) designation for ALLO-316 based on clinical data from the TRAVERSE trial indicating its to address the unmet need for adult patients with advanced or metastatic CD70 positive RCC who have failed multiple standard RCC therapies, including an immune checkpoint inhibitor and a VEGF-targeting therapy.

ALLO...$3.10...🥳

georgie18

Member Level
Re: georgie18 post# 663652

Tuesday, November 05, 2024 3:37:32 PM

Post#
663738
of 663757
ALLO...$3 ...starting up again...🥳

georgie18

Member Level
Re: georgie18 post# 385217

Tuesday, November 05, 2024 9:15:04 AM

Post#
385226
of 385239
ALLO...$2.98...News...ALLO-316, an “Off-the-Shelf” AlloCAR T™ Anti-CD70 CAR T Product, is Currently Under Investigation in the Phase 1 TRAVERSE Trial for Patients with Renal Cell Carcinoma (RCC) Previously Treated with Immune Checkpoint Inhibitors and VEGF-Targeting Therapies
Data Presented Advances Scientific Understanding and Applicability of the Dagger® Technology as the Next-Generation Allogeneic Platform to Maximize the Potential of a Single Infusion, AlloCAR T Product
Ongoing Phase 1 Data Supported the FDA's Recent RMAT Designation for ALLO-316 as a Promising Treatment to Address an Unmet Medical Need for Adults with Advanced or Metastatic CD70 Positive RCC Who Have Failed Standard RCC Therapies
SOUTH SAN FRANCISCO, Calif., Nov. 05, 2024 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) products for cancer and autoimmune disease, today announced that it will present new data from the ongoing Phase 1 TRAVERSE trial at the 2024 International Kidney Cancer Symposium (IKCS) and the Society for Immunotherapy of Cancer's (SITC) annual meeting. The trial evaluates ALLO-316, the Company’s first AlloCAR T product candidate for the potential treatment of solid tumors. These presentations will highlight data from 26 heavily pretreated patients with CD70 positive renal cell carcinoma (RCC) and will include details on the diagnostic and treatment algorithm used to mitigate treatment-associated hyperinflammatory response seen in some patients. The ongoing Phase 1 data supported the U.S. Food and Drug Administration’s (FDA) October 2024 decision to grant Regenerative Medicine Advanced Therapy (RMAT) designation for ALLO-316 based on clinical data from the TRAVERSE trial indicating its to address the unmet need for adult patients with advanced or metastatic CD70 positive RCC who have failed multiple standard RCC therapies, including an immune checkpoint inhibitor and a VEGF-targeting therapy.

ALLO...$3 ...starting up again...🥳

georgie18

Member Level
Re: georgie18 post# 385217

Tuesday, November 05, 2024 9:15:04 AM

Post#
385226
of 385239
ALLO...$2.98...News...ALLO-316, an “Off-the-Shelf” AlloCAR T™ Anti-CD70 CAR T Product, is Currently Under Investigation in the Phase 1 TRAVERSE Trial for Patients with Renal Cell Carcinoma (RCC) Previously Treated with Immune Checkpoint Inhibitors and VEGF-Targeting Therapies
Data Presented Advances Scientific Understanding and Applicability of the Dagger® Technology as the Next-Generation Allogeneic Platform to Maximize the Potential of a Single Infusion, AlloCAR T Product
Ongoing Phase 1 Data Supported the FDA's Recent RMAT Designation for ALLO-316 as a Promising Treatment to Address an Unmet Medical Need for Adults with Advanced or Metastatic CD70 Positive RCC Who Have Failed Standard RCC Therapies
SOUTH SAN FRANCISCO, Calif., Nov. 05, 2024 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) products for cancer and autoimmune disease, today announced that it will present new data from the ongoing Phase 1 TRAVERSE trial at the 2024 International Kidney Cancer Symposium (IKCS) and the Society for Immunotherapy of Cancer's (SITC) annual meeting. The trial evaluates ALLO-316, the Company’s first AlloCAR T product candidate for the potential treatment of solid tumors. These presentations will highlight data from 26 heavily pretreated patients with CD70 positive renal cell carcinoma (RCC) and will include details on the diagnostic and treatment algorithm used to mitigate treatment-associated hyperinflammatory response seen in some patients. The ongoing Phase 1 data supported the U.S. Food and Drug Administration’s (FDA) October 2024 decision to grant Regenerative Medicine Advanced Therapy (RMAT) designation for ALLO-316 based on clinical data from the TRAVERSE trial indicating its to address the unmet need for adult patients with advanced or metastatic CD70 positive RCC who have failed multiple standard RCC therapies, including an immune checkpoint inhibitor and a VEGF-targeting therapy.

ALLO...$2.98...News...ALLO-316, an “Off-the-Shelf” AlloCAR T™ Anti-CD70 CAR T Product, is Currently Under Investigation in the Phase 1 TRAVERSE Trial for Patients with Renal Cell Carcinoma (RCC) Previously Treated with Immune Checkpoint Inhibitors and VEGF-Targeting Therapies
Data Presented Advances Scientific Understanding and Applicability of the Dagger® Technology as the Next-Generation Allogeneic Platform to Maximize the Potential of a Single Infusion, AlloCAR T Product
Ongoing Phase 1 Data Supported the FDA's Recent RMAT Designation for ALLO-316 as a Promising Treatment to Address an Unmet Medical Need for Adults with Advanced or Metastatic CD70 Positive RCC Who Have Failed Standard RCC Therapies
SOUTH SAN FRANCISCO, Calif., Nov. 05, 2024 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) products for cancer and autoimmune disease, today announced that it will present new data from the ongoing Phase 1 TRAVERSE trial at the 2024 International Kidney Cancer Symposium (IKCS) and the Society for Immunotherapy of Cancer's (SITC) annual meeting. The trial evaluates ALLO-316, the Company’s first AlloCAR T product candidate for the potential treatment of solid tumors. These presentations will highlight data from 26 heavily pretreated patients with CD70 positive renal cell carcinoma (RCC) and will include details on the diagnostic and treatment algorithm used to mitigate treatment-associated hyperinflammatory response seen in some patients. The ongoing Phase 1 data supported the U.S. Food and Drug Administration’s (FDA) October 2024 decision to grant Regenerative Medicine Advanced Therapy (RMAT) designation for ALLO-316 based on clinical data from the TRAVERSE trial indicating its to address the unmet need for adult patients with advanced or metastatic CD70 positive RCC who have failed multiple standard RCC therapies, including an immune checkpoint inhibitor and a VEGF-targeting therapy.

ALLO...$3...Hitting again...🥳

georgie18

Member Level
Re: None

Wednesday, October 30, 2024 10:54:12 AM

Post#
385056
of 385216
ALLO...$2.93..."W" in play here... https://schrts.co/BrIJNzMB ...Financials will be announced on the 7th of November...28% short...insiders own 34%...Float 138 million...

ALLO...$2.93..."W" in play here... https://schrts.co/BrIJNzMB ...Financials will be announced on the 7th of November...28% short...insiders own 34%...Float 138 million...

ALLO BIO BEASTING

ALLO under $3

ALLO coiled to run

ALLO...$3 Hitting again...🥳

georgie18

Member Level
Re: georgie18 post# 41

Friday, September 27, 2024 3:57:49 PM

Post#
42
of 42
ALLO...$2.90...Setting up for the $3 Break again...🥳

georgie18

Member Level
Re: georgie18 post# 658272

Wednesday, September 25, 2024 10:03:06 AM

Post#
659219
of 659662
ALLO...$2.65...added more here on the dip...🥳

georgie18

Member Level
Re: None

Wednesday, September 18, 2024 1:30:50 PM

Post#
40
of 40
ALLO...$2.79 added the dip ...🥳

ALLO...$2.90...Setting up for the $3 Break again...🥳

georgie18

Member Level
Re: georgie18 post# 658272

Wednesday, September 25, 2024 10:03:06 AM

Post#
659219
of 659662
ALLO...$2.65...added more here on the dip...🥳

georgie18

Member Level
Re: None

Wednesday, September 18, 2024 1:30:50 PM

Post#
40
of 40
ALLO...$2.79 added the dip ...🥳

ALLO...$2.65...added more here on the dip...🥳

georgie18

Member Level
Re: None

Wednesday, September 18, 2024 1:30:50 PM

Post#
40
of 40
ALLO...$2.79 added the dip ...🥳

ALLO...$2.79 added the dip ...🥳

ALLO...$2.98...W pattern still in play here...Looking for $3.23 Break...🥳off the $2.55 alert...

georgie18

Member Level
Re: georgie18 post# 36

Wednesday, September 11, 2024 4:02:04 PM

Post#
38
of 38
ALLO...$2.92...Psar flipped Bullish...Trying for upper bollie break...🥳...

georgie18

Member Level
Re: georgie18 post# 652456

Monday, August 26, 2024 2:22:57 PM

Post#
655267
of 657175
ALLO...$2.79...Off my $2.55...Alert...Still looking for $3 Break...🥳

georgie18

Member Level
Re: georgie18 post# 32

Thursday, August 22, 2024 9:38:16 AM

Post#
33
of 35
ALLO...$2.72s clearing here...🥳

georgie18

Member Level
Re: georgie18 post# 652456

Monday, August 19, 2024 3:08:16 PM

Post#
654171
of 654707
ALLO...$2.60s clearing here...🥳

georgie18

Member Level
Re: None

Tuesday, August 06, 2024 1:20:27 PM

Post#
382404
of 382735
ALLO...$2.55s starting here...coming off the bottom...🥳

ALLO...$2.92...Psar flipped Bullish...Trying for upper bollie break...🥳...

georgie18

Member Level
Re: georgie18 post# 652456

Monday, August 26, 2024 2:22:57 PM

Post#
655267
of 657175
ALLO...$2.79...Off my $2.55...Alert...Still looking for $3 Break...🥳

georgie18

Member Level
Re: georgie18 post# 32

Thursday, August 22, 2024 9:38:16 AM

Post#
33
of 35
ALLO...$2.72s clearing here...🥳

georgie18

Member Level
Re: georgie18 post# 652456

Monday, August 19, 2024 3:08:16 PM

Post#
654171
of 654707
ALLO...$2.60s clearing here...🥳

georgie18

Member Level
Re: None

Tuesday, August 06, 2024 1:20:27 PM

Post#
382404
of 382735
ALLO...$2.55s starting here...coming off the bottom...🥳

ALLO under $3

ALLO...$2.79...Off my $2.55...Alert...Still looking for $3 Break...🥳

georgie18

Member Level
Re: georgie18 post# 32

Thursday, August 22, 2024 9:38:16 AM

Post#
33
of 35
ALLO...$2.72s clearing here...🥳

georgie18

Member Level
Re: georgie18 post# 652456

Monday, August 19, 2024 3:08:16 PM

Post#
654171
of 654707
ALLO...$2.60s clearing here...🥳

georgie18

Member Level
Re: None

Tuesday, August 06, 2024 1:20:27 PM

Post#
382404
of 382735
ALLO...$2.55s starting here...coming off the bottom...🥳

Thanks for posting...🥳

ALLO Current Institutional Ownership Percentage 83.63% up from 63%
187 Institutional Holders 165,517,865 Total Shares Held
https://www.marketbeat.com/stocks/NASDAQ/ALLO/institutional-ownership/

ALLO...$2.72s clearing here...🥳

georgie18

Member Level
Re: georgie18 post# 652456

Monday, August 19, 2024 3:08:16 PM

Post#
654171
of 654707
ALLO...$2.60s clearing here...🥳

georgie18

Member Level
Re: None

Tuesday, August 06, 2024 1:20:27 PM

Post#
382404
of 382735
ALLO...$2.55s starting here...coming off the bottom...🥳

ALLO...$2.60s clearing here...🥳

georgie18

Member Level
Re: None

Tuesday, August 06, 2024 1:20:27 PM

Post#
382404
of 382735
ALLO...$2.55s starting here...coming off the bottom...🥳

ALLO...$2.55s starting here...coming off the bottom...🥳

ALLO under $3

ALLO under $3

ALLO under $3

ALLO new 52 week low

Yes. Signet-ring, TP53. ... dying. Even more aggressive than the ones enrolled in CART trial

Was that the case study (50-year-old female)?

I know the CAR-T is already in registrational trials both in China and the US. If all goes to plan, they expected to submit an NDA to the NMPA in 2024 and a BLA to the FDA in 2025. A next-gen version is in the clinic as well https://aacrjournals.org/clincancerres/article/26/20/5494/82735/Coexpression-of-IL7-and-CCL21-Increases-Efficacy

Also https://www.biospace.com/article/moderna-carsgen-join-forces-combining-mrna-cancer-vaccine-with-car-t/

However, it's getting pretty crowded

https://x.com/ny1972_47/status/1707238076190175679?s=20

Upcoming https://www.globenewswire.com/news-release/2023/09/27/2750477/0/en/Allogene-Therapeutics-Announces-Three-Poster-Presentations-from-its-Next-Generation-AlloCAR-T-Platform-at-the-Society-for-Immunotherapy-of-Cancer-SITC-Annual-Meeting.html

short 49% Mentioned by Roensche Capital

https://www.benzinga.com/quote/ALLO/analyst-ratings

An oral presentation at AACR next month https://www.abstractsonline.com/pp8/#!/10828/presentation/10251

A proprietary approach to control rejection https://www.globenewswire.com/news-release/2022/11/10/2553356/0/en/Allogene-Therapeutics-Unveils-Novel-Approach-to-Generate-Engineered-AlloCAR-T-Cells-to-Control-Immune-Rejection-at-the-Annual-Meeting-of-the-Society-for-Immunotherapy-of-Cancer.html

This is one of a number of next-gen technologies being pioneered. Others, include https://www.globenewswire.com/en/news-release/2023/02/01/2599947/0/en/Allogene-Therapeutics-Presents-Data-on-Dagger-a-Next-Generation-AlloCAR-T-Platform-Technology.html

R&D showcase PR https://www.globenewswire.com/news-release/2022/11/29/2564467/0/en/Allogene-Therapeutics-R-D-Showcase-Features-Hematologic-and-Solid-Tumor-Advances-Across-its-AlloCAR-T-Platform.html

Slides https://ir.allogene.com/static-files/3eacf8bf-3cd0-47bc-a5ac-f5715083883a

ASGCT PR https://www.globenewswire.com/news-release/2022/05/19/2446950/0/en/Allogene-Therapeutics-Announces-Oral-Presentation-of-Pre-Clinical-Data-Highlighting-Improved-Anti-Tumor-Activity-of-Donor-Derived-Allogeneic-CAR-T-Cells-at-American-Society-of-Gene.html

New preclinical data https://aacrjournals.org/cancerrescommun/article/2/3/158/684708/Allogeneic-Anti-BCMA-CAR-T-Cells-Are-Superior-to

Additional data https://allogene.com/resources/download/ALPHA-Study.pdf https://allogene.com/resources/download/ALPHA2-Study.pdf https://allogene.com/resources/download/UNIVERSAL-Updated-Phase-1-Data-Validates-Feasibility-Allogeneic.pdf
https://ir.allogene.com/static-files/891ef05d-ff61-4c95-9a55-9ff7a515102d

AS PR's https://www.globenewswire.com/news-release/2021/12/13/2350984/0/en/Allogene-Therapeutics-Reports-Positive-Results-from-Phase-1-UNIVERSAL-Study-of-Single-Dose-ALLO-715-AlloCAR-T-Cell-Therapy-in-Relapsed-Refractory-Multiple-Myeloma-at-the-63rd-Ameri.html

https://www.globenewswire.com/news-release/2021/12/13/2350962/0/en/Allogene-Therapeutics-Reports-Positive-Phase-1-Data-from-the-ALPHA-Trials-in-Non-Hodgkin-s-Lymphoma-at-the-63rd-Annual-Meeting-of-the-American-Society-of-Hematology.html

Abstracts

ALPHA2 Study: ALLO-501A Allogeneic CAR T in LBCL, Updated Results Continue to Show Encouraging Safety and Efficacy with Consolidation Dosing https://ash.confex.com/ash/2021/webprogram/Paper146045.html

ALPHA Study: ALLO-501 Produced Deep and Durable Responses in Patients with Relapsed/Refractory Non-Hodgkin’s Lymphoma Comparable to Autologous CAR T https://ash.confex.com/ash/2021/webprogram/Paper146038.html

Universal Updated Phase 1 Data Validates the Feasibility of Allogeneic Anti-BCMA ALLO-715 Therapy for Relapsed/Refractory Multiple Myeloma https://ash.confex.com/ash/2021/webprogram/Paper145572.html

ASH data https://www.globenewswire.com/news-release/2021/11/04/2327658/0/en/Allogene-Therapeutics-to-Showcase-Clinical-Data-from-the-ALPHA-ALPHA2-and-UNIVERSAL-AlloCAR-T-Trials-at-the-63rd-Annual-Meeting-of-the-American-Society-of-Hematology.html

$ALLO: 2nd day of bouncing off bottom...... now $17.25



GO $ALLO

New PR https://www.globenewswire.com/news-release/2021/06/04/2242102/0/en/Allogene-Therapeutics-Presents-Positive-Phase-1-Data-on-ALLO-501-and-ALLO-501A-in-Relapsed-Refractory-Non-Hodgkin-Lymphoma-at-the-2021-Annual-Meeting-of-the-American-Society-of-Cli.html

Posters https://www.allogene.com/resources/download/First-In-Human-Data-of-ALLO-501A.pdf https://www.allogene.com/resources/download/Safety-and-PK-PD-of-ALLO-647.pdf